Phase 1 Relapsed or Refractory Clinical Trials
49 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 49 trials
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 1
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim187 enrolled13 locationsNCT07306559
Recruiting
Phase 1
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
Chongqing Precision Biotech Co., Ltd15 enrolled1 locationNCT07715630
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Excyte Biopharma Ltd48 enrolled1 locationNCT06565689
Recruiting
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Relapsed or Refractory Multiple Myeloma
Genentech, Inc.120 enrolled14 locationsNCT05927571
Recruiting
Phase 1
Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
Relapsed or Refractory AML and Other Hematologic Malignancies
Kyowa Kirin Co., Ltd.156 enrolled17 locationsNCT06812104
Recruiting
Phase 1
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
MSD R&D (China) Co., Ltd.100 enrolled15 locationsNCT06189391
Recruiting
Phase 1Phase 2
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
Extranodal NK T Cell LymphomaNK/T-cell LymphomaRelapsed or Refractory NK/T-Cell Lymphoma
Rong Tao107 enrolled1 locationNCT07502768
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 1
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
Refractory Immune-mediated Platelet Transfusion RefractorinessRelapsed or Refractory Immune Thrombocytopenia
The First Affiliated Hospital of Soochow University9 enrolled1 locationNCT07072247
Recruiting
Phase 1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116
Recruiting
Phase 1Phase 2
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC155 enrolled3 locationsNCT07439653
Recruiting
Phase 1
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
Relapsed or Refractory CD19+ B-cell LymphomaRelapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma
University Health Network, Toronto19 enrolled1 locationNCT05963217
Recruiting
Phase 1
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
Relapsed or Refractory Follicular Lymphoma
University of Pennsylvania6 enrolled1 locationNCT07343934
Recruiting
Phase 1
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC80 enrolled15 locationsNCT06604715
Recruiting
Phase 1
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Advanced Solid TumorRelapsed or Refractory Lymphomas
Lantern Pharma Inc.110 enrolled1 locationNCT06132503
Recruiting
Phase 1
U96-CAR-T-Cells For R/R B-ALL
Relapsed or Refractory B Cell Leukemia and Lymphoma
The First Affiliated Hospital of Soochow University30 enrolled1 locationNCT07511426
Recruiting
Phase 1
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals42 enrolled11 locationsNCT03838926
Recruiting
Phase 1
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.130 enrolled11 locationsNCT06375044